BR112012002333A2 - método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. - Google Patents

método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.

Info

Publication number
BR112012002333A2
BR112012002333A2 BR112012002333A BR112012002333A BR112012002333A2 BR 112012002333 A2 BR112012002333 A2 BR 112012002333A2 BR 112012002333 A BR112012002333 A BR 112012002333A BR 112012002333 A BR112012002333 A BR 112012002333A BR 112012002333 A2 BR112012002333 A2 BR 112012002333A2
Authority
BR
Brazil
Prior art keywords
subject
disease associated
macrophages
macrophage
disease
Prior art date
Application number
BR112012002333A
Other languages
English (en)
Inventor
Ari Azhir Arasteh
S Mcgrath Michael
Original Assignee
Neuraltus Pharmaceuticals Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuraltus Pharmaceuticals Inc, Univ California filed Critical Neuraltus Pharmaceuticals Inc
Publication of BR112012002333A2 publication Critical patent/BR112012002333A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
BR112012002333A 2009-08-06 2010-07-23 método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. BR112012002333A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23198909P 2009-08-06 2009-08-06
US23267809P 2009-08-10 2009-08-10
US23860909P 2009-08-31 2009-08-31
PCT/US2010/043150 WO2011017030A2 (en) 2009-08-06 2010-07-23 Treatment of macrophage-related disorders

Publications (1)

Publication Number Publication Date
BR112012002333A2 true BR112012002333A2 (pt) 2017-07-18

Family

ID=43544843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002333A BR112012002333A2 (pt) 2009-08-06 2010-07-23 método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.

Country Status (10)

Country Link
US (2) US20120134929A1 (pt)
EP (1) EP2461694A4 (pt)
JP (1) JP2013501046A (pt)
CN (1) CN102573500A (pt)
AU (2) AU2010281524A1 (pt)
BR (1) BR112012002333A2 (pt)
CA (1) CA2770023A1 (pt)
EA (1) EA201290041A1 (pt)
IL (1) IL217824A0 (pt)
WO (1) WO2011017030A2 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130028864A1 (en) * 1998-04-08 2013-01-31 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating brain inflammation
JP4991544B2 (ja) 2004-08-23 2012-08-01 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EA201290041A1 (ru) 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
US20130244965A1 (en) * 2010-09-28 2013-09-19 The General Hospital Corporation Assays and methods for determining risk of a macrophage-mediated disease development in a subject infected with hiv
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US9642780B2 (en) 2011-06-15 2017-05-09 Rls Global Ab Detection and removal of carious dentin tissue
WO2012177565A2 (en) * 2011-06-20 2012-12-27 California Institute Of Technology Regulation of macrophage activation using mir - 125b
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013109949A1 (en) * 2012-01-19 2013-07-25 Ibt Usa Inc. Therapeutic uses of tetrachlorodecaoxygen (tcdo)
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
SE536581C2 (sv) 2012-07-24 2014-03-11 Rls Global Ab Ett kit för behandling av sår eller liknande och ett preparat och metoder därav
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN105102984B (zh) * 2012-12-28 2018-03-02 美迪恩斯生命科技株式会社 sCD14或它的片段或衍生物用于风险分级、诊断和预后的用途
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9925202B2 (en) * 2013-03-04 2018-03-27 Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN104208050A (zh) * 2013-05-30 2014-12-17 曲建宁 叔丁基-4-羟基苯甲醚新用途
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3019167T3 (da) * 2013-07-12 2021-03-15 Knopp Biosciences Llc Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
CN105813659A (zh) 2013-08-20 2016-07-27 J·D·李 用于改善呼吸系统健康状况并提高脊椎动物的肺中低硫氰酸盐离子浓度的方法
CN106102737B (zh) 2013-10-22 2019-06-14 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US20150148304A1 (en) * 2013-10-24 2015-05-28 Soligenix, Inc. Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
CN103926408A (zh) * 2014-04-30 2014-07-16 天津医科大学肿瘤医院 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用
US20170071975A1 (en) * 2014-05-12 2017-03-16 Steerwasher, Llc Compositions and methods for treating depressive disorders
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
JP6445840B2 (ja) * 2014-10-29 2018-12-26 持田製薬株式会社 プレセプシン測定による血球貪食症候群の検出
CN107427221B (zh) * 2015-01-09 2021-03-09 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
CA2995659A1 (en) * 2015-08-20 2017-02-23 Oxo Chemie (Thailand) Co., Ltd Use of chlorite to treat red blood cell diseases and indications mediated thereby
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
JP2019506861A (ja) 2016-02-01 2019-03-14 シーダーズ−サイナイ メディカル センター マイクロ流体装置における腸細胞の成長のためのシステム及び方法
WO2017147169A1 (en) * 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
DE102016205950A1 (de) 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
WO2018140647A1 (en) 2017-01-25 2018-08-02 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
US11414648B2 (en) 2017-03-24 2022-08-16 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
KR20200011492A (ko) * 2017-06-22 2020-02-03 새미 랩스 리미티드 소포체 스트레스의 치료학적 관리를 위한 가르시놀 조성물
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
US10676744B2 (en) * 2017-10-13 2020-06-09 University Of South Carolina Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)
AU2019227186A1 (en) * 2018-02-27 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
US20210033628A1 (en) * 2018-04-30 2021-02-04 Cedars-Sinai Medical Center Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease
CN112424608A (zh) * 2018-05-10 2021-02-26 卫理公会医院 用于疾病的预后和管理的方法
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
WO2020018434A1 (en) * 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
JP2022521831A (ja) * 2019-03-29 2022-04-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 標的指向性協働的がん免疫療法
WO2020218232A1 (ja) * 2019-04-23 2020-10-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチ治療のためのバイオマーカー
JP2022544169A (ja) 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防
CN112386606A (zh) * 2019-08-19 2021-02-23 卢序 一种有第二信使作用增加积极氧化压力的氧化剂的用途
WO2021072650A1 (zh) * 2019-10-15 2021-04-22 湖南乾康科技有限公司 中间型单核细胞在制备诊断和预测ad药物中的应用
CN111202840A (zh) * 2019-11-22 2020-05-29 上海市第六人民医院 一种库弗细胞活性抑制剂及其在制备治疗急性肝衰竭药物中的应用
CN110859847B (zh) * 2019-12-18 2022-11-08 中国药科大学 一种治疗高血糖症合并动脉粥样硬化的药物组合及其应用
US20210315921A1 (en) * 2020-04-13 2021-10-14 Edifice Health, Inc. Compounds and Methods for Modifying iAge
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
WO2022005875A1 (en) * 2020-06-30 2022-01-06 The Regents Of The University Of California Chlorite in the treatment of acute respiratory distress syndrome
EP4192472A1 (en) * 2020-08-10 2023-06-14 Reverspah LLC Method and composition for treating corona virus, influenza, and acute respiratory distress syndrome
CN112043689B (zh) * 2020-08-26 2022-10-04 广东工业大学 一种用于抑制脂多糖诱导巨噬细胞炎症的药物组合物及其应用
KR20230169147A (ko) * 2021-03-11 2023-12-15 더 메서디스트 하스피틀 질환 치료를 위한 방법 및 조성물
WO2022235761A1 (en) * 2021-05-07 2022-11-10 University Of North Texas Health Science Center At Fort Worth Precision medicine approach to treating parkinson's disease with a monoamine oxidase inhibitor, an antioxidant, or both
CN115364096B (zh) * 2021-05-19 2024-04-05 同济大学 一种改善Wolfram综合征中胰岛β细胞凋亡情况的药物
CN114191618A (zh) * 2021-06-01 2022-03-18 四川大学华西医院 一种减缓纤维化和炎性巨噬细胞募集的改性骨修复材料
CN113786490A (zh) * 2021-09-14 2021-12-14 华中科技大学同济医学院附属协和医院 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用
CN114594266B (zh) * 2022-03-02 2022-12-27 安徽中医药大学第一附属医院(安徽省中医院) M1联合m2型巨噬细胞因子作为生物标志物在类风湿关节炎诊断和治疗监测中的用途
WO2024072910A1 (en) * 2022-09-27 2024-04-04 Marv Enterprises, LLC Composition for Acutely Decreasing Pathophysiologic Effects from a Concussion and a Method of Administering Thereof
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用
WO2024108035A1 (en) * 2022-11-17 2024-05-23 Erx Pharmaceuticals, Inc Compositions and methods for treatment of prader-willi syndrome
CN116875542B (zh) * 2023-09-08 2023-11-10 苏州依科赛生物科技股份有限公司 一种间充质干细胞培养增强剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213389A1 (de) 1982-04-10 1983-10-20 Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten
DE4208828A1 (de) 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5667817A (en) * 1992-03-20 1997-09-16 Alcide Corporation Method and composition for prevention and treatment of female lower genital tract microbial infections
US6099855A (en) 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5855922A (en) 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
DE69821506T2 (de) * 1997-10-06 2004-12-16 Oxo Chemie Ag Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DE60332385D1 (de) 2002-12-02 2010-06-10 Bharat Serums & Vaccines Ltd Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
CA2634915A1 (en) * 2005-12-22 2007-07-05 Taiji Biomedical, Inc. Chlorite formulations, and methods of preparation and use thereof
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
EA201290041A1 (ru) 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами

Also Published As

Publication number Publication date
CN102573500A (zh) 2012-07-11
AU2016202631A1 (en) 2016-05-19
CA2770023A1 (en) 2011-02-10
EA201290041A1 (ru) 2012-07-30
US20150037320A1 (en) 2015-02-05
AU2010281524A1 (en) 2012-02-23
US9579346B2 (en) 2017-02-28
EP2461694A4 (en) 2013-06-19
IL217824A0 (en) 2012-03-29
WO2011017030A2 (en) 2011-02-10
WO2011017030A3 (en) 2011-06-03
US20120134929A1 (en) 2012-05-31
EP2461694A2 (en) 2012-06-13
JP2013501046A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
BR112012002333A2 (pt) método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
BRPI0910198A2 (pt) composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
PA8778101A1 (es) Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
BR112012017073A2 (pt) Método de tratamento de condições neurológicas com glicosídeos cardíacos
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BR112012031103A2 (pt) método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
BR112013023724A2 (pt) métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MY160894A (en) Oligosaccharide composition for treating skin diseases
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
BRPI0822162A2 (pt) Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
BR112014015940A8 (pt) composição de novo fármaco de carboidrato para tratamento de doenças humanas
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
BR112013010918B8 (pt) composição compreendendo sal de cloridrato de alumínio, método de fabricação do referido sal e usos do mesmo
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
AR086543A1 (es) Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
BR112012027648A2 (pt) composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112014012746A2 (pt) nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp
BR112014010729A2 (pt) métodos para tratamento de ataques de gota

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]